Abstract: The present invention is directed to a composition comprising a modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: The invention concerns methods of treating suicidal ideation or behavior in a subject in need thereof, comprising decreasing endogenous nicotinic acetylcholine receptor (nAChR) activity in the subject; therapeutic packages for treating suicidal ideation or behavior; and methods for determining the efficacy of a treatment for suicidal ideation or behavior. In some embodiments, the treatment methods comprise administering to the subject an effective amount of an inhibitor of a nAChR, such as a lithium compound, mecamylamine, clozapine, or asenapine.

Abstract: Described herein are novel methods and formulations for reducing suicidality in human subjects. Such formulations and methods are a combination of lithium and one or more other CNS therapeutic agents such as anti-depressant, mood-stabilizing, anxiolytic, anticonvulsant, antipsychotic, anti-addictive, and appetite suppressant drugs.

Abstract: A first aqueous solution filled in an electrolytic cell (2) is electrolyzed by applying DC voltage between the electrodes 7a and 7b in said electrolytic cell 2, to form an oxidation field short of electrons in said aqueous solution; and then, a second aqueous solution with carboxylic acid dissolved in it is mixed into the first aqueous solution in oxidation field state, so that the first aqueous solution in oxidation field state obtains electrons and is deoxidized, and the carboxylic acid is oxidized, to produce carbonic acid gas in said aqueous solution. Therefore, the present invention can be used to produce carbonic acid gas solution at a low cost easily.

Abstract: The present invention relates to improved methods of preventing or inhibiting the release of acid in the stomach, which are uniquely reversible at the cellular level, through the use of organic isothiocyanates and thiocyanates with divalent cations such as barium, zinc and calcium for human and veterinary applications. The present invention also relates to methods of preventing or treating persistent chronic gastritis, GERDs, ulcer and or stomach cancer by inhibiting the release of stomach acid and by reducing inflammation with fewer and milder side-effects expected than current treatments. A method of screening therapeutics is described.

Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.

Abstract: The present invention is directed to a treatment composition for recreational water, comprising a high molecular weight water soluble resin composition made from long chain alkoxylated polymers or co-polymers that impart emollient properties to the recreational water, as well as articles of manufacture comprising packaging material and the treatment composition for recreational water contained within the packaging material. The present invention is also directed to methods for treating recreational water, and recreational water treated with the above treatment composition.

Abstract: The invention provides compositions for inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, comprising an effective amount of a redox-sensitive purine compound and an effective amount of a redox agent. The invention further provides methods of inhibiting a redox-sensitive GTPase protein, including a Rho or Rab family GTPase, by administering compositions of the invention. Methods of screening for compounds that inhibit a redox-sensitive GTPase protein, including compounds that target and inhibit Rho or Rab family GTPases, are further provided.

Abstract: This disclosure relates to personal grooming apparatus that include coatings on the surface thereof that incorporate calcium carbonate derived from the shell of a mollusk and/or from a mollusk pearl. Other aspects of the present disclosure relate to methods for producing such apparatus, and methods of grooming the hair or skin of an individual.

Abstract: The present invention describes the isolation and characterization of the novel biopesticide compositions and/or biopesticide formulations obtained from Eucalyptus species capable of serving as effective biocontrol agents and/or pest control management agents. The invention focuses on the isolation of these biopesticide compositions and formulations that are known to possess pesticidal properties and are derived from natural sources having biological origin. The invention more particularly describes the isolation and characterization, including but not confined to, novel biopesticide compositions possessing pesticidal attributes along with other pharmaceutically important attributes so as to also function as effective biocontrol agents.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage for in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.

Abstract: Controlling insects of the superfamily of the Psylloidea in horticultural and/or agricultural crops, by using bicarbonate and carbonate salts.

Abstract: The present invention relates to a solid, ingestible composition comprising a) an alginate; b) a bicarbonate; and c) a carbonate wherein the composition is in the form of a chewable core, a process for preparing said composition, and its use in the treatment of reflux oesophagitis, gastritis, dyspepsia or peptic ulceration or for use as a sustained releasing or targeted delivery composition.

Abstract: Disintegrable preparations of lanthanum carbonate prepared by co-precipitation, facilitating the manufacture of oral pharmaceutical dosage forms such as tablets, capsules, powders, granules, and sprinkles, and the use of such dosage forms to treat subjects with hyperphosphatemia are disclosed.

Abstract: This invention provides coral-based scaffolds for cartilage repair, and instruments for insertion and utilization of same within a site of cartilage repair.

Abstract: The present invention relates to a method of suppressing appetite or promoting a stimulant effect in an individual in need thereof, comprising administering to the individual per 24 hour period an effective amount of one or more alkali metals selected from the group consisting of one or more sources of cesium, one or more sources of rubidium, one or more sources of lithium, and combinations thereof. The present invention further relates to weight loss or stimulant compositions comprising one or more alkali metals.

Abstract: The present invention relates to new morphinan modulators of NMDA receptors, ?1 receptors, ?2 receptors, and/or ?3?4 nicotinic receptors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Methods and compositions for treating wounds, decubitus ulcers, diaper rash, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates in one embodiment the use of an aqueous or emollient medium having one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface.

Abstract: The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Compositions and methods for the treatment of fracture and metastatic bone cancer are disclosed.

Abstract: A cosmetic capsule which can be topically applied and rubbed in and comprises a casing material and a filling material enclosed by the casing material. The casing material is composed of an emulsion which comprises one or more waxes that are solid above 25° C. and the filling material comprising a preparation which has an abrasive effect and comprises one or more abrasive peeling agents which are present in an oil or lipid mixture, a surfactant-containing preparation or an emulsion.

Abstract: Embodiments described include devices and methods for forming a porous polymer material. Devices disclosed and formed using the methods described include a spacer for spinal fusion, craniomaxillofacial (CMF) structures, and other structures for tissue implants.

Abstract: The subject application provides methods of identifying compounds, combinations of compounds, compositions, and/or combinations of compositions that are suitable for reducing the production of reactive oxygen species (ROS) in an individual with the proviso that said compound, combination of compounds, composition, or combination of compositions is not a dietary material containing calcium or dietary calcium. Also provided in the subject application are methods of treating diseases or disorders associated with ROS production and methods of reducing ROS production in an individual with the proviso that said compound, combination of compounds, composition, or combination of compositions is not a dietary material containing calcium or dietary calcium.

Abstract: The subject application provides a method of identifying or screening compounds or compositions suitable for reducing the production of reactive oxygen species (ROS) comprising: a) feeding (or orally administering) compositions comprising dietary material containing dietary calcium (or dietary calcium) to at least one subject; b) measuring intracellular concentrations of calcium in cells of said at least one subject, wherein a decrease of intracellular calcium concentration in said cells of said at least one test subject as compared to the intracellular concentrations of calcium in the cells of at least one control subject is indicative of a compound, composition, combination of compounds or combination of compositions suitable for use in reducing the production of ROS in a subject. Methods of treating ROS-related diseases comprising the oral administration of dietary material containing dietary calcium (or dietary calcium) are also provided.

Abstract: Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize ?-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.

Abstract: The present invention discloses a coating for a medical implant, wherein at least a part of said coating contains an osseointegration agent and the same and/or a different part of the coating contains an antimicrobial metal agent.

Abstract: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) ionic compound, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.

Abstract: A method for combating unwanted conditions downstream of the mouth with adhering troches. A method to treat or reduce replication of a virus in throat tissues by releasing an anti-viral from an adhering disc. A method to treat sore throat with time release of Glycyrrhiza extract or collagen from an adhering disc. A method to treat sore throat with topically applied cobalamin. An adhering troche that releases antacid, alginate, bismuth subsalicylate, soluble zinc, such as zinc gluconate, bioactive vitamin B12 (methylcobalamin), antibiotic, or anti-viral. A method to combat bacterial effects downstream of the mouth with topically applied xylitol.

Abstract: The present invention relates to the use of a pharmaceutical composition comprising at least one strontium salts for the preparation of a medicament for treatment and prevention of gingivitis, periodontitis (aggressive and chronic), periodontitis as a 5 manifestation of systemic diseases and/or necrotizing periodontal diseases. The composition preferably comprises strontium carbonate, strontium chlorides and/or strontium renalate. Further included may be a vitamin D compound, preferably vitamin D3.

Abstract: The present invention relates to new thienobenzodiazepine modulators of D1 receptors, D2 receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.

Abstract: Described is a layered or segmented controlled release pharmaceutical tablet adapted for separating one segment from another by breaking through a segment.

Abstract: A composition comprising an antacid, and a local, topical anesthetic. The composition is used to relieve pain or discomfort associated with a sore throat, and therefore, the invention is also directed to a method of alleviating the pain or discomfort associated with a sore throat comprising instructing a human to orally administer the composition.

Abstract: Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces.

Abstract: A composition comprising an antacid, and a local, topical anesthetic. The composition is used to relieve pain or discomfort associated with a sore throat, and therefore, the invention is also directed to a method of alleviating the pain or discomfort associated with a sore throat comprising instructing a human to orally administer the composition.

Abstract: A method for fabricating a substitute component for bone, including the processes of: provision of a chemical spray including at least three of calcium chloride, hydrogen phosphate, hydrogen carbonate and water to form a combined solution; reaction and precipitation of the combined solution onto a substrate; allowing the precipitated particles to form a porous structure on the substrate; applying substantially isostatic pressure to the porous structure to form a compressed structure; and (optional) providing one or more through-holes in the compressed structure to promote osteoinduction.

Abstract: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.

Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.

Abstract: The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation. In vivo methods for reducing rejection of transplanted cord blood stem cells by administering a lithium salt after transplantation are also provided.

Abstract: The present invention features methods of delivering corticosteroids or metabolites thereof for treating and preventing tissue damage resulting from acute radiation injury in the gastrointestinal tract with locally effective therapeutic agents.

Abstract: The present invention relates to new dibenzo[b,e][1,4]diazepine modulators of dopamine receptors, serotonin receptors, adrenergic receptors, acetylcholine receptors, and/or histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention relates to new pyrrolidinone inhibitors of PDE-4 activity, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention relates to new benzisoxazole modulators of D2 receptors and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuropsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

Abstract: The present invention includes a method of maintaining rumen health in ruminants. The method includes providing to a ruminant a low-moisture block made of molasses and having a buffer. The low-moisture buffer block is specifically designed such that licking rather than chewing consumes the block. The licking action of the cows increases salivation, which acts as a natural buffer for the maintenance of the overall rumen health.

Abstract: The present invention relates to new 3H-benzooxazol-2-one modulators of D2 receptors and/or 5-HT1A receptors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising a phosphate binder and another pharmaceutically active ingredient. The other pharmaceutically active ingredient is selected from a group consisting of antihypertensives, calcitrol, vitamin D analogues, lipid restriction products, potassium salts, treatments for anemia and alkalization compounds.

Abstract: The present invention is drawn to disinfectant or sterilant compositions, which are human safe, e.g., food grade or food safe. In one embodiment, an aqueous disinfectant or sterilant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 50 wt % of a peracid, and from 0.001 wt % to 25 wt % of a peroxide. Additionally, from 0.001 ppm to 50,000 ppm by weight of a transition metal based on the aqueous vehicle content can also be present. The composition can be substantially free of aldehydes. Alternatively or additionally, the transition metal can be in the form of a colloidal transition metal.